Sanofi has announced an increase in net income from continuing operations for the fourth quarter (Q4) of 2024, reaching €880m ...

Earnings Call Transcript January 30, 2025 Sanofi misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were ...

Analyst Graham Parry of Bank of America Securities reiterated a Buy rating on Sanofi (SNYNF – Research Report), boosting the price target to ...

Shares of US drugmaker Vertex Pharmaceuticals jumped 8.4% to $475.00 in after-hours trading yesterday after it announced that ...

The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...

Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant Approval based on positive results from the IMROZ phase 3 study ...

Montelukast does not appear to increase the risk for neuropsychiatric adverse events in children and adolescents, according to a study published in JAMA Pediatrics. Montelukast is a leukotriene ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.

New US President Donald Trump and his administration have confirmed that lowering the cost of prescription drugs for Americans is a top priority, suggesting that they will continue the work of the ...